Up to a $1.7 billion collaboration was terminated when Sanofi canceled an agreement with Lexicon Pharmaceuticals to develop Zynquista™ (sotagliflozin) after type 1 and type 2 diabetes candidate showed mixed results in three Phase III trials, including disappointing...